Table 1.
Genomic alterations deemed to be potentially productively therapeutically targetable
| Mutation/ Alteration | Corresponding targeted agents | Histology: DTC/PDTC, 25 ATC, 19 MTC, 8 | No. of alterations |
|---|---|---|---|
| AURKB | Pazopanib, AMG900 | ATC (vus) | 1 |
| ALK | Crozotinib Ceritinib Alectanib | ATC (vus) | 1 |
| BRAFV600E | Vemurafenib dabrafenib | PTC ATC | 10 (40%) 6 (32%) – |
| BRCA1-2 | Olaparib Rusaparib Nuraparib | PTC (vus) PDTC (vus) HCC (vus) | 1 2 1 |
| ERBB2-3 | Trastuzumab Pertuzumab | ATC (vus) ATC/PTC (vus) | 2 2 |
| FGF/R | Pazopabib Ciritinib | PTC (vus) PDTC (vus) ATC (vus) | 2 1 3 |
| JAK | Roxolitinib Tofacitinib | PTC (vus) ATC (vus) | 4 1 |
| MSH2/6 | (Confers increased sensitivity to anti–PD-L1/PD-1 therapy) Pembrolizumab Nivolumab | PTC PDTC ATC ATC (vus) ATC/PTC (vus) | 1 1 1 1 1 |
| MTOR | Everoliums Temsirolimus | PTC ATC/PTC (vus) | 2 1 |
| PDGFRA/B | Pazopanib Lenvatinib | ATC/PDTC | 1 |
| PI3K | Alpelisib | ATC/PTC | 2 |
| RET | Vandetanib Cabozantinib, LOXO-292 BLU-667 | HCC (vus) ATC (vus) ATC/PTC (vus) MTC | 1 1 1 3 |
| ROS | Crozotinib Ciritinib Alectanib | PDTC (vus) | 1 |
| TOP2A | Etoposide Doxorubicin | ATC/PTC (vus) | 1 |
Abbreviations: ATC, anaplastic thyroid cancer; DTC, differentiated thyroid cancer; HCC, Hürthle cell cancer; MTC, medullary thyroid cancer; PDTC, progression to poorly differentiated thyroid cancer; PTC, papillary thyroid cancer; vus, variant of uncertain significance.